Factors influencing the decision to share cancer genetic results among family members: an in ‐depth interview study of women in an Asian setting

CONCLUSIONSFacilitators and barriers for result‐sharing are similar to those among Western women. A framework to explain Asian patients' decision‐making process identifies optimal counselling opportunities to enhance communication with family.
Source: Psycho-Oncology - Category: Cancer & Oncology Authors: Tags: PAPER Source Type: research

Related Links:

Use of low-dose aspirin is associated with a reduced risk of ovarian cancer, results from a cohort study show.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
Authors: Zou T, Wang PL, Gao Y, Liang WT Abstract Long noncoding RNAs (LncRNAs) are involved in the occurrence and progression of human tumors including ovarian cancer (OC). Long noncoding RNA HOTTIP has been found to be involved in several human tumors development. However, the role of HOTTIP in OC remains large unknown. In the present study, our results observed that lncRNA HOTTIP expression levels were notably higher in ovarian cancer tissue samples compared to adjacent normal tissue samples. Increased lncRNA HOTTIP expression levels were significantly associated with advanced FIGO stage and lymph node metastasi...
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Authors: Cosgrove CM, O'Malley DM Abstract INTRODUCTION: Rucaparib is increasingly being utilized for women with recurrent ovarian cancer both as treatment and maintenance therapy. PARP inhibitors like rucaparib are daily oral medication that exploit the DNA repair pathway. The most significant clinical benefit is in those tumors exhibiting deficiency in their homologous recombination pathway. Areas covered: This review will discuss the mechanism of action, clinical efficacy data and safety of rucaparib as presented from phase 1, 2, and phase 3 clinical trials. Expert opinion: Rucaparib is a promising therapeutic o...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Conditions:   Ovarian Cancer;   Ovarian Carcinoma;   Ovary Cancer;   Endometrial Cancer;   Endometrioid Adenocarcinoma;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma Intervention:   Drug: STRO-002 Sponsor:   Sutro Biopharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractOvarian cancer is a leading cause of death among gynecologic malignancies. This disappointing prognosis is closely related to intrinsic or acquired resistance to conventional platinum-based chemotherapy, which can affect a third of patients. As such, investigating relevant molecular targets is crucial in the fight against this disease. So far, many mutations involved in ovarian cancer pathogenesis have been identified. Among them, a few pathways were implicated. One such pathway is the P13K/AKT/mTOR with abnormalities found in many cases. This pathway is considered to have an instrumental role in proliferation, mig...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsWe confirmed that gBRCA1/2 deficiency and advanced stage are independent risk factors for development of carboplatin hypersensitivity in ovarian cancer patients. Our study also shows improved OS in hypersensitive patients receiving CD compared to non-hypersensitive patients, independent of gBRCA1/2.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
AbstractOlaparib (Lynparza ®), a first-in-class poly (ADP-ribose) polymerase (PARP) inhibitor, has recently been approved in a new tablet formulation as maintenance treatment for recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platin um-based chemotherapy. Relative to an earlier capsule formulation, the tablet formulation of olaparib has improved bioavailability, thereby reducing pill burden and offering a more convenient dosage regimen. In the phase III SOLO2 study, maintenance treatment with olaparib tablets significantly pro...
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThis is the first report describing acquired resistance to immunotherapy in MMR-D pancreatic cancer with accompanying genomic and immune profiling. This case of oligoprogression in the setting of immunotherapy demonstrates the feasibility of localized treatment followed by continuation of immunotherapy to sustain ongoing response.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsOur data indicated that hepatectomy is safe for NCNNLM and that patient prognoses vary depending on the type of primary tumors. Indications for hepatectomy should be determined with reference to survival rates and risk factors specific to each of the various types of primary tumor.
Source: Journal of Hepato-Biliary-Pancreatic Surgery - Category: Surgery Authors: Tags: Original Article Source Type: research
A pooled analysis of two randomized trials found that neoadjuvant chemotherapy and upfront debulking surgery yield similar outcomes in patients with advanced tubo-ovarian cancer, except in some settings.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
More News: Cancer | Cancer & Oncology | Genetics | Men | Ovarian Cancer | Ovaries | Study | Women